Capacities of somatostatin analogues to treat castration-resistant prostate cancer

Close metadata

Recommended articles:

The syndrome of psycho-sensory-anatomical-functional auto-desadaptation in patients with malignant tumors of the maxillofacial region. Stomatology. 2024;(4):20-27

Cost of supportive cancer care in the Russian Federation. Part 2. Medical Technologies. Assessment and Choice. 2024;(4):63-73

Transfusion therapy of the XIX century — the beginning of the formation of parenteral nutrition for surgical patients. Pirogov Russian Journal of Surgery. 2025;(3):156-163

The effect of the iron III polysaccharide complex use on the cytokines, natriuretic peptide and erythropoietin levels in patients with chronic heart failure accompanied with anemia. Russian Journal of Preventive Medicine. 2025;(3):80-86

Iron supplements and erythropoiesis-stimulating agents in intensive care of postpartum hemorrhage: a Bayesian network meta-analysis. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):59-67

Anemia is common in malignant diseases, particularly in most patients receiving chemotherapy. The paper discusses the causes of anemia in cancer patients, its treatments, including packed red blood cell transfusion, erythropoietic stimulants, and intravenous iron preparations.

Keywords:

malignant tumors

anemia

hemotransfusion

erythropoietic stimulants

iron preparations

Authors:

Moiseev S.V.

Kafedra terapii i profbolezneĭ Pervogo moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, MGU im. M.V. Lomonosova

SPIN RSCI: 3462-7884
Scopus AuthorID: 7102097492
ResearcherID: H-3040-2013
ORCID: 0000-0002-7232-4640

List of references:

Knight K., Wade S., Balducci L. Prevalence and outcomes of anaemia in cancer: a systematic review of the literature. Am. J. Med. 2004; 116 (suppl. 7A): 11S-26S.
Tas F., Eralp Y., Basaran M., Sakar B., Alici S., Argon A. et al. Anaemia in oncology practice: relation to diseases and their therapies. Am. J. Clin. Oncol. 2004; 2 (suppl. 1): 11-26.
Ludwig H., van Belle S., Barrett-Lee P., Birgegård G., Bokemeyer C., Gascón P. et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer. 2004; 40 (15): 2293-306.
Varlotto J., Stevenson M. Anemia, tumor hypoxemia, and the cancer patient. Int. J. Radiat. Oncol. Biol. Phys. 2005; 63 (1): 25-36.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cancer- and chemotherapy-induced Anemia. Version 2.2012 (R). www.NCCN.org.
Miller Y., Bachowski G., Benjamin R. et al. Practice Guidelines for Blood Transfusion: A compilation from recent peer-reviewed literature. 2-nd ed. American National Red Cross; 2007.
Wiesen A., Hospenthal D., Byrd J., Glass K.L., Howard R.S., Diehl L.F. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann. Intern. Med. 1994; 121: 278-30.
Aapro M., Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008; 13 (suppl. 3): 33-6.
Hebert P., Wells G., Blajchman M., Marshall J., Martin C., Pagliarello G. et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N. Engl. J. Med. 1999; 340: 409-17.
Novik A.V. Anemiya i metabolicheskie rasstroistva u onkologicheskikh bol'nykh. Prakticheskaya onkologiya. 2009; 10 (3): 131-40.
Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist. 2011; 16 (suppl. 3): 12-8.
Churchhousea A., Mathewsa T., McBridea O., Dunning J. Does blood transfusion increase the chance of recurrence in patients undergoing surgery for lung cancer? Interactive Cardiovasc. Thorac. Surg. 2012; 14: 85-90.
Bohlius J., Tonia T., Schwarzer G. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients. Acta Haematol. 2011; 125: 55-67.
Bohlius J., Wilson J., Seidenfeld J., Piper M., Schwarzer G., Sandercock J. et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst. 2006; 98: 708-14.
Bennett C., Silver S., Djulbegovic B., Samaras A.T., Blau C.A., Gleason K.J. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. J.A.M.A. 2008; 299: 914-24.
Tonelli M., Hemmelgarn B., Reiman T., Manns B., Reaume M.N., Lloyd A. et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a metaanalysis. Can. Med. Assoc. J. 2009; 180: E62-71.
Ludwig H., Crawford J., Osterborg A., Vansteenkiste J., Henry D.H., Fleishman A. et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebocontrolled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J. Clin. Oncol. 2009; 27: 2838-47.
Glaspy J., Crawford J., Vansteenkiste J., Henry D., Rao S., Bowers P. et al. Erythropoiesisstimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer. 2010; 102: 301-15.
Milovanov Yu.S., Milovanova L.Yu., Kozlovskaya L.V. Nefrogennaya anemiya: patogenez, prognosticheskoe znachenie, printsipy lecheniya. Klinicheskaya nefrologiya. 2010; 6: 7-18.
Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J. et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009; 373: 1532-42.
Food and Drug Administration. Epoetin alfa label. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103234Orig 1s5166_103234Orig1s5266lbl.pdf.
Schrijvers D., de Samblanx H., Roila F., on behalf of the ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann. Oncol. 2010; 21 (suppl. 5): v244-7.
Aapro M., Osterborg A., Gasco P., Ludwig H., Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann. Oncol. 2012. doi:10.1093/annonc/mds112.
Beale A., Penney M., Allison M. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal. Dis. 2005; 7: 398-402.
Ludwig H., Muldur E., Endler G. et al. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status. Haematologica. 2011; 96: abstr. 982.
Anker S., Comin C., Filippatos G., Willenheimer R., Dickstein K., Drexler H. et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 2009; 361: 2436-48.
Moiseev S.V. Zheleza karboksimal'tozat (Ferinzhekt) - novyi vnutrivennyi preparat dlya lecheniya zhelezodefitsitnoi anemii. Klinicheskaya farmakologiya i terapiya. 2012; 21 (2): 48-53.
Coyne D. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int. 2011; 80 (3): 240-4.
Dvoretskii L.I. Zhelezodefitsitnaya anemiya v praktike terapevta. Russkii meditsinskii zhurnal. 2009; 23: 1517-21.
Grasso P. Sarcoma after intramuscular iron injection. Br. Med. J. 1973; 2: 667.
Auerbach M., Ballard H., Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007; 369: 1502-4.
Geisser R. The pharmacology and safety profile of ferric carboxymaltose (Ferinject®): structure/reactivity relationships of iron preparations. Port. J. Nephrol. Hypert. 2009; 23 (1): 11-6.
Hedenus M., Birgegård G. The role of iron supplementation during epoietin treatment for cancer-relatedanemia. Med. Oncol. 2009; 26 (1): 105-15.
Auerbach M., Ballard H., Trout J., McIlwain M., Ackerman A., Bahrain H. et al. Intravenous iron optimizes the response to recombinant human erythropoietinin cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 2004; 22 (7): 1301-7.
Henry D., Auerbach M., Tchekmedyiand S., Laufmane L. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007; 12 (2): 231-42.
Petrelli F., Borgonovo K., Cabiddu M., Lonati V., Barni S. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J. Cancer Res. Clin. Oncol. 2012; 138 (2): 179-87.
Hedenus M., Nasman P., Liwing J. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. J. Clin. Pharm. Ther. 2008; 33: 365-74.
Auerbach M., Ballard H., Trout J., McIlwain M., Ackerman A., Bahrain H. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 2004; 22: 1301-7.
Bailie G., Horl W., Verhof J. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. Drug Res. 2011; 61: 267-75.

Close metadata